Cwm LLC Boosts Stake in United Therapeutics Corporation $UTHR

Key Points

• Cwm LLC increased its stake in United Therapeutics Corporation by 204.3% during the 2nd quarter, now holding shares worth approximately $1.49 million.
• Multiple hedge funds have also made significant moves recently, with institutional investors owning 94.08% of United Therapeutics' stock as of the latest filings.
• Analysts generally have a Moderate Buy consensus rating for United Therapeutics, with a target price range between $330.00 and $580.00.

Cwm LLC boosted its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 204.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,194 shares of the biotechnology company's stock after purchasing an additional 3,487 shares during the period. Cwm LLC's holdings in United Therapeutics were worth $1,492,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Chung Wu Investment Group LLC purchased a new position in United Therapeutics during the 2nd quarter valued at $29,000. SVB Wealth LLC bought a new stake in shares of United Therapeutics during the first quarter worth $32,000. Geneos Wealth Management Inc. boosted its stake in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 85 shares during the period. Brooklyn Investment Group boosted its stake in shares of United Therapeutics by 103.2% during the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 98 shares during the period. Finally, WPG Advisers LLC bought a new position in shares of United Therapeutics in the first quarter worth about $60,000. Institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on UTHR. UBS Group lifted their price objective on shares of United Therapeutics from $560.00 to $580.00 and gave the company a "buy" rating in a report on Monday, September 29th. Oppenheimer boosted their price target on United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Bank of America increased their price objective on United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 2nd. Jefferies Financial Group lifted their target price on United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. dropped their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Nine investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $461.62.

United Therapeutics Stock Down 0.1%

NASDAQ UTHR opened at $432.69 on Tuesday. The firm has a market cap of $19.52 billion, a PE ratio of 16.89, a price-to-earnings-growth ratio of 4.72 and a beta of 0.66. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48. The company has a 50 day moving average price of $388.34 and a 200 day moving average price of $329.17.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same period in the previous year, the company posted $5.85 earnings per share. The business's revenue for the quarter was up 11.7% on a year-over-year basis. On average, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction dated Thursday, October 16th. The shares were sold at an average price of $431.50, for a total transaction of $4,746,500.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $15,871,001.50. This represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction that occurred on Monday, October 13th. The stock was sold at an average price of $440.35, for a total transaction of $9,907,875.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 307,435 shares of company stock worth $125,401,167. 10.30% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.